检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:赵敏 李江 章建军[1] 谢升阳[1] ZHAO Min;LI Jiang;ZHANG Jianjun;XIE Shengyang(The First Affiliated Hospital of Zhejiang Chinese Medical University(Zhejiang Proviacial Hospital of Chinese Medicine),Hangzhou 310000,China)
机构地区:[1]浙江中医药大学附属第一医院(浙江省中医院),杭州310000
出 处:《中国现代应用药学》2023年第3期394-398,共5页Chinese Journal of Modern Applied Pharmacy
基 金:浙江省药学会医院药学专项科研资助项目(2022ZYY27)。
摘 要:目的 基于FAERS数据库研究仑伐替尼与结肠炎之间的关系。方法 基于2015年1季度—2021年3季度的FAERS数据,检索使用仑伐替尼后报告结肠炎的病例,使用比例失衡法和贝叶斯法进行数据挖掘。同时评估结肠炎的发生时间、仑伐替尼的使用剂量和患者结局。结果 共检索到101例仑伐替尼相关结肠炎病例。仑伐替尼使用后结肠炎报告例数逐年增加,这些病例大多数由医师提交。住院或住院延长(77例,76.24%)是最常见的不良事件报告结局。4种算法均检测到仑伐替尼的结肠炎不良事件信号(ROR=3.66,95%CI=3.01~4.46;PRR=3.63,χ^(2)=189.96;IC=1.86,IC025=1.53;EBGM=3.62,EBGM05=3.07)。仑伐替尼用量≥12 mg的有66例,占比82.50%。结肠炎发生时间大多数≤60 d,占比58.21%。结论 仑伐替尼与结肠炎存在相关性,在使用仑伐替尼时,应考虑其诱发结肠炎的可能性,并仔细监测结肠炎或腹部症状的迹象。OBJECTIVE To investigate the relationship between lenvatinib and colitis based on the FAERS database.METHODS Based on FAERS data from 2015 q1 to 2021q3,the cases of colitis reported following lenvatinib were retrievaled and the disproportionality and Bayesian analysis were employed for data mining.The onset time to colitis,the dose of lenvatinib using and the patient outcomes were also evaluated.RESULTS A total of 101 cases of lenvatinib-associated colitis were retrieved.The number of reported cases of colitis following lenvatinib had increased year by year,and most of these cases were submitted by physicians.Hospitalization or prolonged hospitalization(77,76.24%) was the most common adverse event reported outcome.All 4 methods found an association between lenvatinib and colitis(ROR=3.66,95%CI=3.01-4.46;PRR=3.63,χ^(2)=189.96;IC=1.86,IC025=1.53;EBGM=3.62,EBGM05=3.07).The 66 patients(82.50%) received lenvatinib dose more than 12 mg.Most of the colitis occurred within 60 d,accounting for 58.21%.CONCLUSION There is a correlation between lenvatinib and colitis.When lenvatinib is used,colitis should be considered and patients receiving lenvatinib should be carefully monitored for signs of colitis or abdominal symptoms.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.90